Drug class
Polymyxins
Polymyxins are a class of cyclic polypeptide antibiotics, principally represented in clinical use by polymyxin B and colistin (polymyxin E). Read more about Polymyxins
16 drugs in this class 13 manufacturers
Drugs in Polymyxins
COLISTIMETHATE (colistin (as colistimethate sodium))
COLY-MYCIN M PARENTERAL (colistin (as colistimethate sodium))
COLISTIMETHATE (colistin (as colistimethate sodium))
COLISTIMETHATE (colistin (as colistimethate sodium))
POLYMYXIN B SULFATE
POLYMYXIN B SULFATE
POLYMYXIN B SULFATE
POLYMYXIN B SULFATE
Polymyxins are a class of cyclic polypeptide antibiotics, principally represented in clinical use by polymyxin B and colistin (polymyxin E).
They exert bactericidal activity by binding directly to the lipopolysaccharide and phospholipids of the bacterial outer membrane, disrupting membrane integrity and causing leakage of intracellular contents.
Due to their efficacy against challenging pathogens, polymyxins serve as critical reserve agents for severe, multidrug-resistant Gram-negative infections, notably those involving *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and carbapenem-resistant Enterobacterales.
Systemic administration is typically reserved for hospitalized patients with life-threatening infections, such as hospital-acquired pneumonia, bacteremia, and complicated urinary tract infections, where other antimicrobial options are ineffective or contraindicated.
-
fda.gov
Polymyxins are a class of cyclic polypeptide antibiotics, principally represented in clinical use by polymyxin B and colistin (polymyxin E)
-
nih.gov
Polymyxins are a class of cyclic polypeptide antibiotics, principally represented in clinical use by polymyxin B and colistin (polymyxin E)
-
nih.gov
They exert bactericidal activity by binding directly to the lipopolysaccharide and phospholipids of the bacterial outer membrane, disrupting membrane integrity and causing leakage of intracellular contents
-
nih.gov
They exert bactericidal activity by binding directly to the lipopolysaccharide and phospholipids of the bacterial outer membrane, disrupting membrane integrity and causing leakage of intracellular contents Systemic administration is typically reserved for hospitalized patients with life-threatening infections, such as hospital-acquired pneumonia, bacteremia, and complicated urinary tract infections, where other antimicrobial options are ineffective or contraindicated
-
fda.gov
Due to their efficacy against challenging pathogens, polymyxins serve as critical reserve agents for severe, multidrug-resistant Gram-negative infections, notably those involving *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and carbapenem-resistant Enterobacterales
-
nih.gov
Due to their efficacy against challenging pathogens, polymyxins serve as critical reserve agents for severe, multidrug-resistant Gram-negative infections, notably those involving *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and carbapenem-resistant Enterobacterales Systemic administration is typically reserved for hospitalized patients with life-threatening infections, such as hospital-acquired pneumonia, bacteremia, and complicated urinary tract infections, where other antimicrobial opt...
-
fda.gov
Systemic administration is typically reserved for hospitalized patients with life-threatening infections, such as hospital-acquired pneumonia, bacteremia, and complicated urinary tract infections, where other antimicrobial options are ineffective or contraindicated
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.